Clinical Evaluation of BRL29060A (paroxetine hydrochloride hydrate) in social phobia/social anxiety disorder - A double-blind, placebo-controlled study- phase III study.

Trial Profile

Clinical Evaluation of BRL29060A (paroxetine hydrochloride hydrate) in social phobia/social anxiety disorder - A double-blind, placebo-controlled study- phase III study.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Paroxetine (Primary)
  • Indications Social phobia
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 06 Jul 2012 Additional trial location (France) identified as reported by ClinicalTrials.gov.
    • 28 Jun 2007 Status changed from in progress
    • 06 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top